Israel reaches agreement to purchase Novavax coronavirus vaccines
time of publication: September 19, 2021, 08:35 | last updated: September 19, 2021 08:36 am blog printable photo
Israel reaches agreement to purchase Novavax coronavirus vaccines
The Israeli authorities have reached an agreement with the American company Novavax to purchase a vaccine against the company's coronavirus. The final contract with Novavax will be signed after the budget is allocated for the purchase of this vaccine.
The Ministry of Health is asking the government to conclude a contract as soon as possible, fearing the emergence of a new strain of coronavirus, against which the vaccines already purchased by Israel will not work.
Novavax has yet to file an FDA application.
According to the results of the third phase of clinical trials, the effectiveness of the Novavax vaccine is approximately 90%, including against new strains of coronavirus,
The Novavax vaccine, unlike the Pfizer and Moderna vaccines already used in Israel, is not based on mRNA technology. Novavax's drug is based on an inactivated coronavirus. It is based on the S-protein of the pathogen SARS-CoV-2, presented in the form of recombinant nanoparticles. The vaccine can be stored at 2-8 degrees Celsius. The Novavax vaccine is given in two doses.
Recall that negotiations with Novavax were launched by the Israeli government in the fall of 2020.
https://www-newsru-co-il.translate.goog/health/...eGTRh2Ul-nSMpwCBv6U